Tag Archives: Cancer

Epredia And Paige Announce Global Commercial Distribution Agreement For Digital Pathology Software | Country | Instant News

PORTSMOUTH, NH, 17 March 2021 / PRNewswire / – Epredia, a global leader in precision cancer diagnosis, and Paige, a global leader in AI-based diagnostic software in pathology, today announced that they have signed a commercial distribution agreement for a comprehensive portfolio of Paige diagnostic software solutions.

Under the terms of this agreement, Epredia has been appointed as the global distribution partner of Paige’s entire portfolio of imaging diagnostic solutions. In addition, Epredia will have exclusive distribution rights on Japan. In the second quarter of 2021, Epredia will start commercializing the Paige solution together with Epredia’s existing products. United States of America and the major European powers, further strengthening its comprehensive digital pathology portfolio which includes the best-in-class CE-marked 3DHistech P1000 scanner *.

The Paige portfolio includes the Paige Platform, a comprehensive imaging solution consisting of a fast trackless footprint viewer, storage capabilities and AI-based diagnostic software to help pathologists review cases and support their overall workflow.

The FDA approved and CE marked Paige platform features FullFocus ™, an intuitive and responsive viewer for pathology scanning that supports primary diagnosis and its Data Management solution for pathology scan storage. The Paige platform is designed to be compatible with existing pathology solutions, including most laboratory scanners, monitors and information systems.

Paige’s AI-based diagnostic software solution is designed to increase the number of cases that can be reviewed and with greater confidence and accuracy. Currently Paige Prostate and Paige Breast are CE marked and available for outside clinical use United States of America. Paige Prostate RUO and Paige Breast RUO are research use-only solutions available at United States of America.

“We are very excited to enter into this partnership with Paige to commercialize its highly innovative portfolio of AI-based digital pathology solutions,” he explained. John Marotta, President, Epredia and Chief Executive Officer, PHC Holdings Corporation. “We believe that digital pathology is an important part of future cancer diagnosis that can greatly improve patient care. We see enormous potential in Paige’s portfolio and believe that it complements our portfolio perfectly. This deal provides us with access to a portfolio that is diverse. highly innovative products that enable us to realize our mission to improve lives by improving cancer diagnostics for patients. “

“This commercial partnership with Epredia is an exciting step for Paige and we are delighted to be working with one of the leading companies in the field of anatomical pathology. Epredia’s extensive global commercial reach will support our efforts to expand our geographic footprint,” said Epredia. Leo Grady, Ph.D., Executive Director of Paige. “Our goal is to transform the diagnostic space by offering a portfolio of software applications that help optimize patient outcomes by enabling pathologists to unlock insights from each sample and return results to doctors and patients more quickly. This commercial agreement will help put our solutions into more hands. pathologists around the world to help patients get the most timely and effective treatment. “

* Regulatory requirements for the 3DHistech P1000 scanner vary by country, please contact your commercial partner to confirm use of an approved scanner in your country.

Epredia is a global leader in the field of anatomical pathology, providing comprehensive solutions for precision cancer diagnosis and tissue diagnostics. Supported by major brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, the Epredia portfolio includes microscope slides, instruments and consumables. Epredia was founded following the acquisition of the Pathology Anatomical Pathology business by PHC Holdings by PHC Holdings in 2019. Epredia has its main site at United States of America, that great Britain, German, Switzerland and China with a total of about 1,200 employees. Epredia is committed to achieving its mission of improving lives by improving cancer diagnostics for patients worldwide. For more information about Epredia and its products, please visit www.epredia.com.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from the Memorial Sloan Kettering Cancer Center (MSK). The company makes computational pathology products designed so that patients and their care teams can make effective and more informed treatment decisions. With a new class of AI-based technology positioned to drive the future of diagnostics, Paige created a platform to bring this new technology to pathologists to transform their workflows and increase diagnostic confidence and productivity. Paige’s products provide pathologists and oncologists with insights so that they can arrive efficiently at a more precise diagnosis for a patient. Paige is the first company to receive an FDA breakthrough designation for a computational pathology product.


image source

Popular sunscreen product ‘can cause cancer expiration date’, warns scientists – World News | Instant News

A variety of popular sunscreen products can pose a cancer risk if left on too long, according to a new study.

In groundbreaking research, US and French scientists have found that a number of popular sun lotions contain a chemical called octocrylene.

The researchers say that over time the chemical turns out to be dangerous and carcinogenic when it produces another compound called benzophenone.

Now, scientists are calling for a product ban and want consumers to be aware of the dangers.

In a lesson published in the journal Chemical Research in Toxicology, researchers looked at various well-known brands of sunscreens.

Scientists have issued a warning to consumers after the study
(Image: Getty Images)

They test products from brands including from Garnier, LaRoche-Posay, L’Oreal, and Neutrogena, all purchased from stores in the US and France.

After artificial aging, some scientists discovered a compound used to protect the skin from the sun’s harmful effects, octocrilene, breaking down into benzophenone over time.

Talking to French Info on the research Dr Didier Stien, one of the authors, said: “If it’s on the skin, benzophenone can cause dermatitis. It can cause cancer, especially liver cancer.

“These are molecules that affect thyroid function and interfere with the development of the reproductive organs.

“To our knowledge in the scientific literature and in general, none [before this study] have shown that octocrylon is degraded to benzophenone. “

Dr Stien said that producers and consumers need to be aware that products containing octocrylene and benzophenone can be dangerous and ask them to be banned.

Woman applying sunscreen, center, close-up
Brands tested include those from L’Oreal and Garnier
(Image: Getty Images)

In conclusion, the scientists said: “There is insufficient scientific literature to make the argument that octocrylene / benzophenone products can pose a threat to individual health and society.

“Several jurisdictions, including the Republic of Palau and the Marshall Islands and the US Virgin Islands, have banned octocrylon in sunscreens and cosmetics, effective January 2020.

“It can be agreed that there needs to be more refined and produced data that is rigorous, unbiased about the exposure and toxicity to this chemical and the products that contain it.”

The Cosmetic Toiletry & Perfumery Association has reportedly said that the new study does not show that sunscreens containing octocrylene pose a health risk to humans, only that benzophenone excrement can appear once produced in sunscreen products.


image source

The chemical (Octocrylene) in sunscreen products turns into a carcinogen | Instant News

The octocrylene in sunscreen products turns into a carcinogen

CLIFFORD, VA, UNITED STATES OF AMERICA, March 8, 2021 /EINPresswire.com/ – A popular sunscreen and its anti-aging cream ingredient, Octocrylene, breaks down into toxic chemicals known as carcinogens and endocrine disruptor.

Octocrylene is naturally degraded into the chemical, benzophenone, in more than a dozen popular products, as shown in research published in the journal, Chemical Research in Toxicology, by French and American researchers at the Sorbonne University and the Haereticus Environmental Laboratory. The concentration of benzophenone in the product increases rapidly as the product ages.

Both octocrylene and benzophenone are easily absorbed into the skin. The absorption of benzophenone skin into the body can exceed 70%, according to a topical study conducted by Prof. Howard Maibach and colleagues in the 1990s – a strong argument for the prohibition of this chemical in perfumes and other topical products.

Based on the US Federal Register of February 26, 2019, Octocrylene does not yet meet the US Food & Drug Administration’s criteria for safety or effectiveness, and accumulated science suggests that it can act as a reproductive toxicant, as well as a metabolic and endocrine disruptor. The octocrilene product tainted by benzophenone calls into question the overall safety of this product for general use. As of 2019, nearly 3,000 commercial products sold in the United States contain octocrilene, including shampoos, hair conditioners, and hair sprays.

Dermatologist, Dr. Sharyn Laughlin, is very concerned about the broad consequences of this research. “Benzophenone is still the worst cause of contact dermatitis, and can cause uticaria and anaphylaxis. The absorption of these two chemicals through the skin poses a potential threat to toxicity and diseases of other organs. ”

Benzophenone is listed as a carcinogen and developmental disruptor under the California Proposition 65. In mammalian model studies, exposure to benzophenone rapidly leads to liver cancer and lymphoma. Benzophenone can act as a photo mutagen; in the presence of light, it increases the rate of DNA lesions, thereby increasing the risk of skin cancer.

Benzophenone is also an endocrine disruptor, affects thyroid function and triggers anti-androgenic activity, slows testicular development and causes anatomical difficulties in the female reproductive organs.

In court cases and product data sheets, the industry has acknowledged that its octocrilene product may be contaminated with benzophenone.

Octocrylene can be removed from personal care product formulations. “It is a challenge to formulate a sunscreen that is both aesthetically pleasing and effective without using endocrine disrupting chemicals, but it can be done,” said Autumn Blum, CEO of Stream2Sea. “It is possible that producers and suppliers of key ingredients can pay attention to science that clearly demonstrates the dangers, and that industry will need to invest in the innovations needed to develop products that are safe for consumers and ecosystems.”

Octocrylene has been banned in sunscreen products in places such as the US Virgin Islands, the Republic of the Marshall Islands, and was first banned in the Republic of Palau. President Tommy Remengesau, Jr., who signed the ban into law, stated, “Palau identifies an emerging environmental threat that is uniquely related to tourism: the use of sunscreens in outdoor recreation. Precautionary management of these chemicals and other contaminants of concern is not only a sound policy, but also embodies the traditional Pacific paradigm of conservation management. We must insist on intensive and independent studies of the safety of all chemicals used in personal care products, and emerging research like this one only reinforces that imperative. Science comes first, we can’t make a bet on environmental health. “

Octocrylene, by itself, has shown toxicity to reproductive development, as well as endocrine disruptive actions. Octocrylene can act as a metabolic poison on corals, potentially reducing the resilience of coral reefs to climate change. Monsanto Chemical Company patented benzophenone as an herbicide in 1954, recognizing the threat that octocrylon-based products polluting the environment could cause less coral bleaching due to benzophenone contamination.

In Hawai’i, State Senator Mike Gabbard, Chair of the Agriculture and Environment Committee, introduced a new law for 2021 that seeks to amend Law 104 by including a banned octocrylonic product, along with oxybenzone and octinoxate sunscreens. Senator Gabbard said, “In 2018, our state became the world leader in safe sunscreens with the enactment of Law 104, which prohibits the hazardous chemicals oxybenzone and octinoxate starting January 1 this year. I introduce SB 366 at this session to take the next step in protecting human health and our environment. “


Craig Downs
Heretical Environmental Laboratory
[email protected]
Visit us on social media:


image source

Football: New Zealand defender Stott is diagnosed with Hodgkin’s lymphoma | Instant News

MELBOURNE: New Zealand and Brighton & Hove Albion defender Rebekah Stott said on Wednesday (March 3) that she had been diagnosed with stage 3 Hodgkin lymphoma, a type of cancer, and had to undergo four months of chemotherapy.

The 27-year-old received his medical report while in quarantine in England but returned to his Australian home last month to seek treatment.

Stott represented Australia at youth level before playing for New Zealand, his home country, at senior level. He won the W-League title three times with Melbourne City from 2016 to 2018.

“I know something is wrong. I have two big lumps on my neck that are growing,” said Stott, who has 71 caps for New Zealand, in a video on Twitter.

“I was actually in quarantine when I got the results that I had been diagnosed with Hodgkin’s lymphoma.

“I know it won’t be easy but I really want to go through this with a positive attitude and try and encourage and inspire others to be able to do the same.”


image source

US Cancer Drug Approval Confirms Access but Not Value | Instant News

Cancer drugs that have been approved in the United States are often not immediately approved in England and Canada, due to uncertainty over benefits and disadvantages and very high prices, two new studies enter Internal Medicine JAMA show.

The US Food and Drug Administration’s (FDA) Food and Drug Administration’s (FDA) oncology approval process was “broken,” concluded accompanying editorial.

“Many cancer drugs are marketed in the United States and, ultimately, globally at unaffordable prices with great uncertainty about their benefits and harms,” ​​said editorial, Vinay Prasad, MD, MPH, University of California, San Francisco, and Myung Kim. . , MD, Oregon University of Health and Science, Portland, Oregon.

“A US drug approval system with uncertain clinical benefit followed by Medicare mandated guarantees without the ability to negotiate prices ensures access,” they observed.

“It is less clear that the US system benefits patients with cancer,” they concluded.

In addition, use of these cancer drugs “is often delayed in high-income Western countries because of reasoned and persistent doubts about its value,” they continued.

“We have to consider the possibility that our drug policy will negatively impact cancer patients worldwide,” they wrote.

Negative impact

The negative impact of the FDA’s drug approval process is most clearly seen in learn from Canada. As analyzed by Daniel Meyers, MD, University of Calgary, Alberta, Canada, and colleagues, between 2011 and 2020, the Pan-Canadian Oncology Drug Review (pCODR) issued 104 replacement recommendations for cancer drugs indicated for solid tumors.

“Three-quarters of all submissions received positive recommendations,” reported investigators. However, more than 92% of approvals were conditional, most often because of serious doubts about the cost-effectiveness of the drug, they wrote.

In addition, only half of the cancer drugs recommended by pCODR improve overall survival (OS), and the improvement in survival is usually modest. Median OS was only 3.7 months, and median progression-free survival (PFS) was only 4.7 months; This figure is not much different from drugs that receive negative recommendations, Meyers and colleagues point out.

Importantly, nearly 40% of cancer drugs that received a positive recommendation from pCODR did not reach the threshold for substantial clinical benefit, as assessed by the European Society for Medical Oncology – Magnitude of Clinical Benefit Scale.

These results suggest that despite the pCODR framework, which provides reimbursement recommendations based on clinical benefit, cost-effectiveness, and patient-based value, “cancer drugs without significant patient benefit continue to be substituted in the Canadian market,” the authors concluded.

In Study in the UK, Avi Cherla, MSc, London School of Economics and Political Science, London, United Kingdom, and colleagues compared the indications for cancer drugs that received FDA accelerated approval from December 1992 to May 2017 with the same indications in the UK to August 2019.

Of the 93 indications for cancer drugs that received FDA accelerated approval over the past 25 years, they found that 30 drug indications were not reviewed for coverage by the UK’s National Health Service (NHS). In addition, 12 indications of drugs were denied authorization or coverage by European regulators or the National Institute for Health and Care Excellence (NICE) because data on safety, clinical efficacy, or cost-effectiveness were insufficient.

Furthermore, NHS coverage for cancer drugs that receive accelerated approval by the FDA often requires additional price concessions, restrictions on drug indications for certain subgroups of patients, and the collection of additional data. As it happened reported, most of the drug approvals by the FDA based on substitute markers, such as tumor shrinkage or delayed tumor growth (PFS), points that Prasad and Kim’s editorial emphasized.

“The surrogate endpoint generates substantial uncertainty about the magnitude of the clinical benefit (if any), which is a key input for cost-effectiveness calculations,” they pointed out.

Perhaps most importantly, “the cancer drugs available in the UK, Canada and the US are not as good as doctors expect for patients,” the editorial wrote. For example, only 34 of the 52 cancer drugs evaluated by NICE showed a survival benefit, and those benefits were at best very modest.

JAMA Intern Med. Published online 22 February 2021. Canadian Studies, Abstract; English Studies, Full text; Editorial

The study authors did not disclose the relevant financial relationships. Prasad has received grants from Arnold Ventures Research and personal expenses from Johns Hopkins Press, Medscape, UnitedHealthcare, New Century Health, and Evicore. She also receives honoraria from medical centers, non-profit organizations, and professional societies and hosts a podcast called Plenary Sessions which has Patreon supporters.

For more information from Medscape Oncology, join us Indonesia and Facebook.


image source